行情

AKBA

AKBA

Akebia
NASDAQ

实时行情|Nasdaq Last Sale

10.28
-0.39
-3.66%
盘后: 10.28 0 0.00% 16:00 08/11 EDT
开盘
10.14
昨收
10.67
最高
10.95
最低
9.89
成交量
139.09万
成交额
--
52周最高
13.71
52周最低
2.990
市值
14.52亿
市盈率(TTM)
-4.6396
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测AKBA价格均价为17.14,最高价位26.00,最低价为12.00。

EPS

AKBA 新闻

更多
Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 4.35% and 18.24%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1天前
Akebia Therapeutics shares are trading lower after the company reported Q2 earnings results. It reported a year over year decrease in Q2 revenue and an increase in net loss and cost of goods sold.
Benzinga · 1天前
Akebia Therapeutics Q2 EPS $(0.44) Beats $(0.50) Estimate, Sales $90.14M Beat $74.18M Estimate
Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.50) by 12 percent. This is a 76 percent decrease over losses of $(0.25) per share from the
Benzinga · 1天前
Akebia Reports Second Quarter 2020 Financial Results
Top-line data readout of global Phase 3
PR Newswire · 1天前
Were Hedge Funds Right About Warming Up To Akebia Therapeutics Inc (AKBA)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter
Insider Monkey · 4天前
Akebia Therapeutics to Report Second Quarter 2020 Financial Results
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report its financial results for the second quarter ended June 30, 2020 on Monday, August
PR Newswire · 08/03 12:00
Biotech Bonanza - Second Half Outlook
Seeking Alpha · 07/28 12:24
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Benzinga · 07/26 13:55

所属板块

生物技术和医学研究
-2.24%
制药与医学研究
-0.89%

热门股票

代码
价格
涨跌幅

AKBA 简况

Akebia Therapeutics, Inc.是一家生物制药公司。该公司专注于开发和销售基于缺氧诱导因子(HIF)的生物学治疗药物。该公司的主要产品候选药物vadadustat被用于治疗慢性肾病(CKD)贫血。该公司从事vadadustat口服制剂的开发业务。该公司的vadadustat是用于治疗CKD贫血的第III期开发HIF-prolyl-hydroxylase(HIF-PH)抑制剂。除了vadadustat之外,该公司还致力于开发基于HIF的针对未满足需求的严重疾病为目标的候选产品组合。该公司的产品组合包括内部开发的候选产品AKB-6899和许可候选产品AKB-5169。AKB-5169是该公司开发的炎症性肠病(IBD)口服治疗剂的临床前化合物。
展开

微牛提供Akebia Therapeutics Inc(NASDAQ-AKBA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的AKBA股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易AKBA股票基本功能。